| Species |
Human |
| Protein Construction |
IL-37b (Val46~Asp218)
Accession # Q9NZH6-1 |
|
| Purity |
> 95% as determined by BisTris PAGE
> 90% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
19.30 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 19.30 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 20mM PB, 150mM NaCl, 2mM DTT (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
IL-37 is a unique member of the IL-1 family of cytokines, which functions as a natural suppressor of inflammatory and immune Interleukin-37 (IL-37), a newly described member of IL-1family, functioned as a fundamental inhibitor of innate inflammatory and immune responses. IL-37 has five different isoforms, and IL-37b is the most biologically functional subtype. IL-37b Inhibits PGN Induced Cytokines and Chemokines via the Downregulation of Intracellular Nuclear Factor (NF)-κB, PI3K–Akt, and ERK1/2 Pathways. |
| Synonyms |
IL-1F7b; IL-HLa; FIL1 zeta; IL-1X; IL-1F7; IL-1H; IL-1H4; IL-1 zeta; IL-1RP1; FIL1Z; IL1F7; IL1H4; IL1RP1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
